News

Transforming Clinical Research with Catalent and Science 37

Transforming Clinical Research with Catalent and Science 37

Revolutionizing Clinical Research

The collaboration between Science 37 and Catalent marks a significant transformation in clinical research, focusing on making participation more accessible for patients everywhere. In an era where convenience and patient-centric approaches are crucial, this partnership is paving the way for a new model of delivering investigational medicinal products (IMPs) directly to participants' homes.

Direct-to-Patient Clinical Trials

This innovative partnership utilizes Science 37's Direct-to-Patient Clinical Trial Site model, enhancing the logistics of clinical trials. By leveraging Catalent's robust shipping and logistics capabilities, medications can be delivered reliably and securely to trial participants. This approach not only increases accessibility but also encourages diverse and representative populations to engage in clinical studies.

Benefits of At-Home Participation

The significant advantage of this direct delivery system is its ability to remove traditional barriers related to location and access. As Tyler Van Horn, CEO of Science 37, states, this method opens doors for a wider range of participant demographics, enabling faster enrollment and better quality data collection. By allowing patients to engage in clinical trials from their homes, the pace at which pharmaceutical and biotech companies can develop new treatments accelerates, ultimately benefiting public health.

Partnership Achievements

Since the inception of their partnership, Science 37 and Catalent have delivered over 6,400 shipments, significantly enhancing trial participation rates. Within just 17 studies conducted, they successfully enrolled nearly 1,700 patients, with an average of 9 participants recruited each month at single Direct-to-Patient Sites. These figures reflect the effectiveness of consolidating trial operations under a single budget and contract, streamlining processes and fostering improved enrollment and retention.

Impact on Clinical Trials

Ricky Hopson, President of Clinical and Specialty Services at Catalent, emphasizes that this partnership not only simplifies the logistics of clinical trials but also transforms the patient experience. Participants are now given a chance to take part in important research without the need to travel to distant clinical sites, creating a more inclusive research environment.

Future of Clinical Research

The implications of this partnership extend far beyond immediate logistics. Science 37 and Catalent are setting benchmarks for a more patient-centered future in clinical research. Their collaborative efforts embody a commitment to quality and precision while ensuring that participants from all walks of life have the opportunity to contribute to the development of life-saving treatments.

Commitment to Health and Innovation

Catalent, as a leading contract development and manufacturing organization, is deeply invested in empowering pharmaceutical and biotech innovations. Their extensive capabilities support over a hundred new product launches each year, ensuring that new advancements in medicine reach populations in need efficiently and effectively.

About Science 37 and Catalent

Science 37 is dedicated to enhancing the clinical research landscape by providing innovative solutions that promote diverse participation in clinical trials. Their commitment to broadening access supports faster approvals and improved health outcomes. On the other hand, Catalent plays a crucial role by delivering high-quality development and manufacturing services that facilitate timely product launches across various sectors.

Frequently Asked Questions

1. What is the role of Science 37 in clinical research?

Science 37 expands patient access to clinical trials, improving the enrollment process and ensuring a diverse participant population.

2. How does the partnership with Catalent enhance clinical trials?

The partnership allows direct delivery of clinical trial medications, simplifying logistics and increasing participant accessibility across geographic areas.

3. What are the benefits of direct-to-patient clinical trials?

This model removes geographical barriers, enhances participant diversity, and allows easier access to trials from the comfort of home.

4. How many shipments have been made under this partnership?

So far, the partnership has successfully delivered over 6,400 shipments to participants involved in clinical trials.

5. What does the future hold for partnerships like Science 37 and Catalent?

Their collaboration signals a movement toward a more inclusive, patient-centered approach in clinical research, which is expected to accelerate the development of new treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 0

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 247

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 240

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 211

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 46

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 140

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 40

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 109

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading

Top 5 Most Recently Viewed Articles

Join the Excitement of the Salt Lake Winter Roundup Event

Updated Category News Views 543

Join the Excitement of the Salt Lake Winter Roundup Event Get ready for a fantastic celebration at the Salt Lake Winter Roundup, an event that promises to be a highlight of the winter season. This all-day festival, taking place on Saturday, February 8, 2025, is set to invigorate downtown Salt Lake with an array of activities and cultural events celebrating the area's rich...

Continue Reading
Statkraft's Strategic Moves Lead to NOK 13.5 Billion Sale

Updated Category News Views 238

Statkraft Reports on Key Asset Divestment Statkraft experienced a notable shift in its operations with a significant divestment reported recently. The company's results in the third quarter demonstrated a decline despite increased power production. This downturn was linked to several factors, including low market prices and reduced contributions from its commercial market...

Continue Reading
Unlocking Wealth: Understanding TE Connectivity's Growth Journey

Updated Category News Views 218

Transforming Investment: The Growth of TE Connectivity TE Connectivity (NYSE: TEL) has shown remarkable performance in the stock market, significantly outpacing the broader market indices over the past fifteen years. With an impressive annual return of 13.74%, this company has established itself as a strong contender in the tech and connectivity industries. Investment...

Continue Reading
Hyperlink InfoSystem Leads California's Software Innovation

Updated Category News Views 128

Hyperlink InfoSystem's Impact on California's Tech Scene In the heart of innovation, California continues to be a significant player in the tech industry, home to numerous landmark companies that shape the future of technology. As digital transformation accelerates across industries, the demand for proficient software development partners has never been so urgent....

Continue Reading
Sola Security Secures $35 Million to Transform Cybersecurity

Updated Category News Views 197

Sola Security's Innovative Funding Round Sola Security, an emerging leader in cybersecurity AI, has made headlines by raising $35 million in a recent Series A funding round. This investment follows their successful $30 million seed round earlier, bringing the total funds raised to a remarkable $65 million. The company plans to use these new resources to further enhance...

Continue Reading